|
Volumn 425, Issue 6954, 2003, Pages 118-120
|
Drug research: The ups and downs of lithium
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ENZYME INHIBITOR;
GLUTAMIC ACID;
GLYCOGEN SYNTHASE KINASE 3;
GLYCOGEN SYNTHASE KINASE 3 INHIBITOR;
INOSITOL;
LITHIUM;
NEUROTRANSMITTER;
UNCLASSIFIED DRUG;
DRUG DEVELOPMENT;
LITHIUM;
ALZHEIMER DISEASE;
BIPOLAR DISORDER;
BRAIN SIZE;
CLINICAL FEATURE;
COMA;
DROWSINESS;
DRUG EFFECT;
DRUG INDUSTRY;
HUMAN;
KIDNEY FAILURE;
NAUSEA;
NONHUMAN;
PRIORITY JOURNAL;
SHORT SURVEY;
SIDE EFFECT;
TREMOR;
VOMITING;
WEIGHT GAIN;
AFFECT;
ANIMAL;
ARTICLE;
BRAIN;
CYTOLOGY;
DRUG ANTAGONISM;
MALE;
METABOLISM;
NERVE CELL;
SECOND MESSENGER;
STEM CELL;
AFFECT;
ALZHEIMER DISEASE;
ANIMALS;
BIPOLAR DISORDER;
BRAIN;
GLYCOGEN SYNTHASE KINASE 3;
HUMANS;
INOSITOL;
LITHIUM;
MALE;
NEURONS;
SECOND MESSENGER SYSTEMS;
STEM CELLS;
|
EID: 0141719652
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/425118a Document Type: Short Survey |
Times cited : (75)
|
References (19)
|